Clinical Trials Logo

Emergency General Surgery clinical trials

View clinical trials related to Emergency General Surgery.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05664360 Completed - Clinical trials for Emergency General Surgery

Incidence and Outcomes of Emergency Department Patients Requiring Emergency General Surgery

Start date: January 1, 2015
Phase:
Study type: Observational

The objectives of this study were (1) to estimate the incidence of emergency general surgery in a Swiss University Hospital, (2) to describe the characteristics and outcomes of patients undergoing such interventions, and (3) to study the impact of age on the outcomes.

NCT ID: NCT04419571 Completed - COVID-19 Clinical Trials

Outcomes in Emergency Laparotomies During COVID-19 Pandemic

Start date: March 23, 2020
Phase:
Study type: Observational

NLR has previously been observed to correlate with complications in upper GI (1) and colorectal (2) surgery. The investigators sought to assess if a similar correlation can be identified in emergency general surgical patients and if the presence of suspected or confirmed COVID-19 may impact on this. Given the heterogeneity of emergency general surgery the investigators therefore plan to perform a retrospective review of patients having emergency laparotomies only at a single NHS site during COVID-19 pandemic. Assessment of outcomes and Neutrophil:lymphocyte ratio as a predictor of outcomes will be completed. Outcomes will be completed in line with the recent COVIDSurg study criteria (3). The primary outcome is 30-day mortality. Secondary outcomes are 7-day mortality, re-operation, length of stay, post-operative respiratory failure, post-operative ARDS (Acute Respiratory Distress Syndrome), post-operative sepsis and ITU (Intensive Therapy Unit)/HDU (High Dependency Unit) admission.

NCT ID: NCT04216394 Completed - Clinical trials for Emergency General Surgery

Anticoagulation in Emergency General Surgery

Start date: October 31, 2019
Phase:
Study type: Observational

While DOACs are increasing in use in the EGS patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. Given the paucity of data regarding the impact of DOACs in this patient population, it becomes empiric to identify bleeding patterns and outcomes in the EGS population taking DOACs. We hypothesize that patients taking a DOAC will have a higher bleeding incidence and need for an unplanned intervention secondary to hemorrhage in EGS patients undergoing an urgent or emergent operation when compared to patients taking warfarin and antiplatelets.